文献速递消化道肿瘤放疗放疗物理与技术

新辅助FOLFIRINOX联合调强放疗同步固定剂量率吉西他滨治疗临界可切除胰腺癌的2期试验

Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-09-05

单中心2期试验纳入25例临界可切除胰腺癌患者,接受6周期FOLFIRINOX后行调强放疗(50 Gy/25次)同步固定剂量率吉西他滨(1 g/m²/100分钟)及后续2次吉西他滨输注。主要终点R0切除率未达55%的替代假设,但切除患者中位OS达37.1个月,方案可行且耐受。

要点

  • 全组中位PFS 13.1个月,中位OS 24.4个月。
  • 3-4级毒性以中性粒细胞减少(40%)、恶心呕吐(28%)常见。

核心结论

  • 新辅助FOLFIRINOX后调强放疗同步固定剂量率吉西他滨治疗临界可切除胰腺癌可行且耐受。
  • 主要终点R0切除率的替代假设未达到,但切除队列的OS良好。

研究设计与样本

  • 单中心、2期试验,纳入25例临界可切除胰腺癌、腺癌确诊、体能状态≤1且器官功能充足的患者。
  • 患者接受FOLFIRINOX 6周期,随后放疗(50 Gy/25次)同步固定剂量率吉西他滨(1 g/m²/100分钟),再行2次吉西他滨输注。
  • 治疗期间每2个月行CT扫描,无远处疾病者接受手术探查;主要终点为R0切除率,替代假设为55%。
  • 试验注册号NCT01661088,入组时间2011年11月至2017年1月。

主要发现

  • 21例(84%)完成FOLFIRINOX,19例(76%)完成全部方案治疗。
  • 治疗相关3-4级毒性包括中性粒细胞减少(40%)、恶心呕吐(28%)、腹泻(16%)、乏力(12%)。
  • 25例患者中位PFS为13.1个月(95%CI 7.3-24.7),中位OS为24.4个月(95%CI 12.6-40.0)。
  • 切除患者中位PFS为21.6个月(95%CI 8.2-37.1),中位OS为37.1个月(95%CI 15.4-未达到)。

关键数值与推荐

  • 主要终点R0切除率未达到55%的替代假设。
  • 放疗剂量为50 Gy分25次,同步吉西他滨为固定剂量率1 g/m²输注100分钟。

临床怎么用

  • 该方案可作为临界可切除胰腺癌新辅助治疗的可选策略之一,需注意血液学和消化道毒性管理。
  • 治疗期间每2个月CT评估,无远处进展者应积极评估手术探查。

局限性

  • 单中心、小样本2期试验,结论需更大规模研究验证。
  • 主要终点R0切除率未达到预设替代假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preoperative therapy in borderline resectable pancreatic cancer (BRPC) is intended to increase R0 resection rates. An optimal approach in BRPC is yet to be defined. METHODS AND MATERIALS: Patients with BRPC, confirmed adenocarcinoma, performance status ≤1, and adequate organ function enrolled in a single-institution, phase 2 trial. Patients received FOLFIRINOX × 6 cycles, then radiation therapy (50 Gy in 25 fractions) concurrent with fixed-dose rate gemcitabine (1 g/m2 over 100 minutes) followed by 2 additional gemcitabine infusions. Computed tomography scans were performed at 2-month intervals during treatment. Patients without distant disease were offered surgical exploration. The primary objective was R0 resection rate with an alternate hypothesis of 55%. Secondary objectives included median progression-free survival (PFS), median overall survival (OS), response rate, and safety. The trial registration number is NCT01661088. RESULTS: Twenty-five patients with median age of 60 years (range, 47-77 years) enrolled from November 2011 through January 2017. Twenty-one (84%) completed FOLFIRINOX and 19 (76%) completed all protocol therapy. Treatment-related grade 3 to 4 toxicities included neutropenia (40%), nausea and vomiting (28%), diarrhea (16%), and fatigue (12%). Eighteen patients (72%) underwent laparotomy, 13 (52%) were resected (all R0). The median PFS and OS in 25 patients were 13.1 months (95% confidence interval [CI], 7.3-24.7) and 24.4 months (95% CI, 12.6-40.0), respectively. For resected patients, median PFS was 21.6 months (95% CI, 8.2-37.1) and OS was 37.1 months (95% CI, 15.4-not reached). CONCLUSIONS: Neoadjuvant therapy with FOLFIRINOX, followed by intensity modulated radiation therapy concurrent with fixed-dose-rate gemcitabine in BRPC is feasible and tolerated. Although the alternate hypothesis was not met, the OS of the resected cohort was favorable.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tran NH, Sahai V, Griffith KA, et al. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31494181. doi:10.1016/j.ijrobp.2019.08.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。